Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma - report from ASH2024

Prof. Meletios-Athanasios Dimopoulos discusses the results of the AQUILA trial, a phase 3 randomized study presented at the 2024 ASH Annual Meeting. New results indicate that these patients not only tolerate daratumumab monotherapy well, but compared with active monitoring, they experience a delay to progression or prevention of active MM. Video: https://medicaldigest.org/scientific-contents/interview:daratumumab-shows-better-outcomes-active-monitoring-smoldering-multiple-myeloma